ADAM10 Inhibition of Human CD30 Shedding Increases Specificity of Targeted Immunotherapy In vitro

Dennis A. Eichenauer,1 Vijaya Lakshmi Simhadri,1 Elke Pogge von Strandmann,1 Andreas Ludwig,2 Vance Matthews,1 Katrin S. Reiners,1 Bastian von Tresckow,1,2 Paul Saftig,2 Stefan Rose-John,1 Andreas Engert,1 and Hinrich P. Hansen1

1Department of Internal Medicine I and 2Center for Molecular Medicine, University Hospital Cologne, Cologne, Germany; 3Department of Biochemistry, University of Kiel, Kiel, Germany; and 4Ludwig Institute for Cancer Research, PO Royal Melbourne Hospital, Victoria, Melbourne, Australia

Abstract

CD30 is a transmembrane protein selectively overexpressed on many human lymphoma cells and therefore an interesting target for antibody-based immunotherapy. However, binding of therapeutic antibodies stimulates a juxtamembrane cleavage of CD30 leading to a loss of target antigen and an enhanced release of the soluble ectodomain of CD30 (sCD30). Here, we show that sCD30 binds to CD30 ligand (CD153)–expressing non-target cells. Because antibodies bind to sCD30, this results in unwanted antibody binding to these cells via sCD30 bridging. To overcome shedding-dependent damage of normal cells in CD30-specific immunotherapy, we analyzed the mechanism involved in the release. Shedding of CD30 can be enhanced by protein kinase C (PKC) activation, implicating the disintegrin metalloproteinase ADAM17 but not free cytoplasmic calcium. However, antibody-induced CD30 shedding is calcium dependent and PKC independent. This shedding involved the related metalloproteinase ADAM10 as shown by the use of the preferential ADAM10 inhibitor GI254023X and by an ADAM10-deficient cell line generated from embryonically lethal ADAM10+/− mouse. In coculture experiments, the antibody-induced transfer of sCD30 from the human Hodgkin's lymphoma cell line L540 to the CD30-negative but CD153-expressing human mast cell line HMC-1 was inhibited by GI254023X. These findings suggest that selective metalloproteinase inhibitors blocking antibody-induced shedding of target antigens could be of therapeutic value to increase the specificity and reduce side effects of immunotherapy with monoclonal antibodies. [Cancer Res 2007;67(1):332–8]

Introduction

A common feature of Hodgkin's lymphoma and large cell anaplastic lymphoma is the strong surface expression of CD30, a type I transmembrane receptor (1). Healthy donors express CD30 exclusively on very few cells, predominantly on activated lymphocytes. In contrast, the cognate ligand (CD153), a membrane-anchored type II glycoprotein, is expressed on the cell surface of many different cell types, including resting B cells, activated T cells, mast cells, monocytes, and granulocytes (2, 3).

Due to its selective expression, CD30 is generally well suited for targeted immunotherapy of CD30-positive lymphomas. Although antibody-based reagents against CD30 showed impressive antitumor activity in experimental Hodgkin's lymphoma models, early clinical trials suffered from dose-limiting toxicities (4). A problem that appeared was the formation of complexes containing the therapeutic antibody and the soluble ectodomain of CD30 (sCD30). sCD30 is generated by proteolytic cleavage of CD30 (5). The release of extracellular domains, also referred to as ectodomain shedding, is a general process regulating the function of membrane proteins (6). In most cases, shedding is catalyzed by metalloproteinases. The tumor necrosis factor-α (TNF-α)–converting enzyme, also known as a disintegrin and metalloproteinase 17 (ADAM17), is the metalloproteinase responsible for the ectodomain release of many membrane proteins, including CD30 (7, 8). A structurally related proteinase (ADAM10) is also implicated in certain shedding processes, such as the non-amyloidogenic processing of Alzheimer's amyloid precursor protein (APP; ref. 9) or the cleavage of N-cadherin and E-cadherin (10, 11).

Many studies distinguish between the mechanisms underlying the constitutive shedding of unstimulated cells and the release from stimulated cells. Classic shedding stimulation is initiated by the protein kinase C (PKC) activator phorbol 12-myristate-13-acetate (PMA), and there is evidence for an implication of ADAM17 (12). In some cases, including CD30, membrane protein shedding is also stimulated by antibody binding (6, 13). As the release of soluble antigen from tumor cells has far-reaching implications for targeted immunotherapy, our group has investigated the use of metalloproteinase inhibitors to block the release of the target antigen (14). In a mouse model, we showed that an anti-CD30 immunotoxin was only effective against human Hodgkin's lymphoma tumors when concomitantly used with the broad-spectrum hydroxamic acid–based metalloproteinase inhibitor BB-3644 (15). Such nonselective inhibitors block many different metalloproteinases, including essential matrix and disintegrin metalloproteinases. They have been used in clinical studies, and the broad specificity resulted in more unspecific toxicity than antitumor effects (16). Thus, more selective inhibitors are desirable for clinical use.

Here, we analyze the mechanism of antibody-stimulated release of sCD30. We found that antibody-induced CD30 shedding was not catalyzed by the previously described ADAM17 but instead by ADAM10. Moreover, we show that immunocompetitive sCD30 not only resided in a soluble form in the pericellular environment but also specifically bound to membrane-anchored CD30 ligand (CD153) on non-target cells where it generated novel targeting sites. Application of an ADAM10-selective metalloproteinase inhibitor significantly reduced this mistargeting.
Materials and Methods

Cells and reagents. We used the CD30+/CD153− cell lines L540 (Hodgkin’s lymphoma) and Karpas 299 (large cell anaplastic lymphoma) and the CD30−/CD153+ cell line DG75 (Burkitt lymphoma) and the CD30−/CD153− cell line Reh (acute lymphoblastic leukemia). In addition, we used the mast cell line HMC-1, which was kindly provided by Dr. J. Butterfield (Mayo Clinic, Rochester, MN); the ADAM17-targeted mouse fibroblast cells, which were received from Dr. R. Black (Ammgen Incorporated, Seattle, WA); and the ADAM10 (−/−) cells, which were a gift of Dr. D. Hartmann (Center for Human Genetics, Leuven, Belgium). The hydroxamate inhibitor BB-3644 [2S-(2,2-dimethyl-propyl)-N-(2,2-dimethyl-1-methylcarbamoyl)-propyl]-N4-hydroxy-3R-methoxy-succinimide] was from British Biotech Pharmaceuticals Ltd. (Oxford, United Kingdom). GW280264 [2(2R,3S)-3-(formyl-hydroxyamino)-2-(2-methyl-1-propyl) hexanoic acid [(1S)-5-(benzyloxy carbamoyl-amino-1-(1,3-thiazol-2-ylcarbamoyl)-1-pentyl amide)] and GI254023X [(2R,3S)-3-(formyl-hydroxyamino)-2-(3-phenyl-1-propyl) butanoic acid [(1S)-2,2-dimethyl-1-methylcarbamoyl-1-propyl] amide] were from GlaxoSmithKline (Stevenage, United Kingdom). Recombinant ADAM10 was from Merck Biosciences (Schwalbach, Germany), and ADAM17 was from R&D Systems (Wiesbaden, Germany).

Plasmids. Construction of recombinant CD30Fc. The CD30Fc fusion protein containing the Fc portion of human IgG1 and the truncated ectodomain of human CD30 (deletion between 89Arg and 156Arg) was expressed in mammalian cells. The expression vector (pBabe-puro, Stratagene, La Jolla, CA) was used to transfect Karpas 299 cells. Cells were transfected with cDNA for enhanced green fluorescence protein (Clontech, Palo Alto, CA) was used to monitor the transfection efficiency. Transfection with cDNA for enhanced green fluorescence protein (Clontech, Palo Alto, CA) was used to monitor the transfection efficiency.

Production and purification of sCD30. 293T cells were transfected with CD30Fc or wild-type CD30 cDNA. After 48 h of incubation, CD30Fc or sCD30 was purified from the supernatants using Protein A Sepharose CL-4B beads (Amersham Pharmacia Biotech) or an anti-CD30 affinity matrix, respectively. In the latter, Ki-1 antibody was covalently linked to the matrix of a HiTrap NHS-activated HP column following the instructions of the manufacturer (Amersham Pharmacia Biotech). The eluted proteins were

Figure 1. Antibody-induced CD30 shedding is calcium dependent and PKC independent. A, stimulation of CD30 shedding. Karpas 299 cells (5 × 10⁶ per mL) were stimulated with Ki-1, PMA, or calcium ionophore (Cal) for different periods of time as indicated. sCD30 was determined in cell-free supernatants. Points, mean for three independent experiments (U/mL); bars, SE. B, shedding inhibition. Karpas 299 cells were stimulated for 40 min with Ki-1 (3 μg/mL), PMA (30 ng/mL), or calcium ionophore (1 μmol/L). Stimulation was done in the presence or absence of BB-3644 (BB; 2 μmol/L), EGTA (EG; 3 mmol/L), or staurosporine (ST; 20 nmol/L). sCD30 was determined in cell-free supernatants. Columns, mean for at least three independent experiments (U/mL); bars, SE. C, induction of Ca²⁺ flux [(Ca²⁺)]i, in FLUO-3/AM–loaded Karpas 299 cells. Cells were stimulated with immobilized Ki-1 (3 μg/mL), PMA (30 ng/mL), or calcium ionophore A23187 (1 μmol/L), and fluorescence was determined by flow cytometry.
CD30 is cleaved by recombinant ADAM10. A, a truncated sCD30Fc protein was constructed. B, the protein (1 μg per lane) was treated with recombinant ADAM10 (70 ng) and ADAM17 (70 ng) for 30 or 90 min. CD30 was determined by Western blotting using a mixture of peroxidase-labeled Ki-2 and Ki-4 antibody. The quantity of the sCD30 bands was evaluated by density scan.

Results

Antibody-induced CD30 shedding is calcium dependent and PKC independent. First, we investigated the release of sCD30 from Karpas 299 cells. All agents, including PMA, the calcium ionophore A23187, and the anti-CD30 antibody Ki-1, stimulated the release of sCD30 in a time- and dose-dependent manner (Fig. 1A). The release was dependent on metalloproteinases because shedding was blocked by the broad-spectrum metalloproteinase inhibitor BB-3644 (Fig. 1B). However, more selective inhibitors indicate differences in the shedding mechanism. The PKC-selective inhibitor staurosporine, an inhibitor of the PMA-stimulated sCD30 release, failed to inhibit the antibody or ionophore effect. On the other hand, EGTA, a calcium-selective chelator, significantly inhibited the antibody or calcium ionophore-induced sCD30 release (both \( P < 0.0001, n = 6 \)) but not the PMA effect (\( P = 0.2597, n = 6 \)). This inhibition profile suggests a role of calcium in antibody but not in PMA-induced CD30 shedding. EGTA inhibition was weaker after antibody stimulation in comparison with that of A23187 treatment. This might be explained by the partially different source of calcium. Although ionophore primarily functions through calcium influx, effectively inhibited by cell membrane-impermeable EGTA, the cell signaling–induced increase in calcium is predominantly recruited from intracellular stores, not chelated by EGTA. In line with this finding, the addition of Ki-1 and ionophore, but not PMA, caused an increase of cytoplasmic calcium levels in Karpas 299 cells (Fig. 1C). This suggests two different shedding pathways for CD30: one that is dependent on calcium but not on PKC, and another one that is dependent on PKC but not on calcium.

Evidence for a role of ADAM10 in antibody-induced CD30 shedding. Because the mechanism of antibody-stimulated CD30 shedding seems to be different from the PMA-stimulated shedding, we evaluated the responsible releasing enzymes. ADAM10 is of particular interest, as the ADAM10-dependent cleavage of CD44 is also associated with elevated cytoplasmic calcium levels (19). We initially compared the potency of recombinant ADAM10 and ADAM17 to cleave a soluble artificial substrate, containing the metalloproteinase-sensitive CD30 stalk domain flanked by a truncated ectodomain of CD30 and the Fc fragment of human IgG1 (Fig. 2A). Both ADAM10 (70 μg/mL) and ADAM17 (70 μg/mL) catalyzed the release of the 35-kDa ectodomain of the recombinant CD30 construct at 37°C in a time-dependent manner (Fig. 2B). The construct alone showed no decomposition within 24 h of incubation (data not shown). Thus, ADAM10 showed CD30 shedding activity that was marginally greater compared with ADAM17, the known CD30 sheddase.

To investigate the role of ADAM10 in lymphoma cell culture, we used an ADAM10-selective inhibitor. This hydroxamic acid–based compound (GI254023X) inhibits ADAM10 >100 times more potently than ADAM17 (20). GI254023X (2 μmol/L) blocked antibody and calcium ionophore–induced shedding (Fig. 3A and B). Moreover, it partially inhibited constitutive CD30 shedding (Fig. 3C) but did not influence the PMA effect (Fig. 3D). Because the broad-spectrum hydroxamate inhibitors BB-3644 and GW280264X, at the same concentration, completely blocked all shedding stimulations in Karpas 299 lymphoma cells, the selective inhibition by GI254023X suggests a role of ADAM10 in anti-CD30 antibody and calcium ionophore–induced CD30 shedding.

Figure 3. Selective inhibition of antibody-stimulated CD30 shedding. Karpas 299 cells were stimulated with Ki-1 (3 μmol/L; A), calcium ionophore (1 μmol/L; B), PMA (30 ng/mL; D), or not stimulated (C) in the presence or absence of the metalloproteinase inhibitors BB-3644 (BB), GI254023X (GI), or GW280264X (GW). Each inhibitor was used at a concentration of 2 μmol/L. sCD30 was determined in cell-free supernatants. Columns, mean for three independent experiments (U/mL); bars, SE.
To confirm the ADAM10 implication in CD30 shedding, we evaluated the release of sCD30 from ADAM10-deficient (ADAM10<sup>−/−</sup>) murine fibroblasts (21, 22) with two different experimental readouts. First, cells were transected with human CD30 cDNA and radiolabeled with a mixture of [<sup>35</sup>S]methionine and [<sup>35</sup>S]cysteine. The cells were then stimulated with Ki-1 antibody or PMA. sCD30 was isolated from cell supernatants by anti-CD30 immunoprecipitation. As shown in Fig. 4A, there is a constitutive liberation of the 90-kDa sCD30 from ADAM10<sup>−/−</sup> cells. This release was enhanced by PMA (×1.3) but not by Ki-1 (×0.8), indicating that antibody-stimulated CD30 shedding is dependent of ADAM10.

Then, a CD30-specific ELISA was used to compare the sCD30 release from ADAM10- or ADAM17-defective cells (Fig. 4B and C). Ki-1, which augments CD30 shedding in Karpas 299 cells, also stimulated the sCD30 release in ADAM10-defective cells (×1.81, P < 0.0001, n = 4). However, in ADAM10-defective cells, the antibody rather caused a mild inhibition (×0.85, P = 0.0001, n = 6; Fig. 4B), confirming a dominating role of ADAM10 in antibody-induced CD30 shedding. PMA, a known stimulator of ADAM10-dependent shedding (7), showed the reverse shedding pattern. This activator enhanced the sCD30 release in ADAM10-defective cells but caused no shedding stimulation in ADAM17-defective cells, rather a reduction (×0.85, P = 0.0002, n = 4). Thus, the data further suggest that there are two different CD30-releasing enzymes: ADAM17, responsible for PMA-induced shedding and ADAM10, responsible for antibody-induced shedding. There is a constitutive release of CD30 found in ADAM10-defective and in ADAM17-defective cells, leading to the conclusion that both enzymes participate.

GI254023X was tested in this knockout setting to confirm its selectivity towards ADAM10 (i.e., inhibition of ADAM10 and non-inhibition of ADAM17). Indeed, it is remarkable that GI254023X at 1 μmol/L showed minor shedding inhibition in ADAM10-defective cells (Fig. 4A and B) but was blocking in ADAM10-expressing but ADAM17-defective fibroblasts (Fig. 4C). Hence, our study shows that GI254023X is a feasible tool to distinguish between ADAM10-defective and ADAM17-catalyzed CD30 shedding.

**sCD30 bridges binding of anti-CD30 antibody to CD30 ligand-expressing cells.** To determine the role of CD30 shedding in tumor cell targeting, we incubated CD30<sup>+</sup> targeting cells or CD30<sup>−</sup> non-targeting cells with sCD30 before staining with FITC-labeled Ki-1 antibody. As shown by flow cytometry, sCD30 (3,000 units/mL) strongly inhibited the binding of Ki-1 antibody to CD30<sup>+</sup> Karpas 299 cells (Fig. 5B). For the CD30<sup>+/CD153</sup> cell lines DG75 and HMC-1, we found the opposite effect. Although generally unable to bind the Ki-1 antibody, sCD30 communicated this binding. The effect was weak and correlated with the expression of CD153 on the cells (Fig. 5A), leading to the suggestion that the anti-CD30 antibody binds to CD153 using sCD30 as a linker. As a control, the CD30<sup>−</sup>/CD153<sup>−</sup> cell line Reh did not bind the antibodies tested.

CD30<sup>−</sup> cells aggregate following incubation with anti-CD30 antibodies (23). As shown in Fig. 5C, the addition of Ki-1 (3 μg/mL) to Karpas 299 cells led to the formation of large homotypic aggregates. This effect was most likely caused by cross-linking membrane-anchored CD30, as the addition of competitive sCD30 (3,000 units/mL) inhibited aggregate formation. We endeavored to visualize sCD30 bridging on CD153<sup>+</sup> cells by means of such homotypic cell aggregation. Ki-1 antibody alone had no influence on the aggregation of the CD30<sup>−</sup> cells HMC-1, DG-75, and Reh. However, on CD153<sup>+</sup> HMC-1 and DG-75 cells, a strong increase of homotypic aggregate formation was observed when sCD30 was applied in addition to the antibody. As a control, the CD30<sup>−</sup>/CD153<sup>−</sup> cell line Reh was not influenced by sCD30 and antibody. These data strongly suggest that sCD30 also functions as a bridging protein in anti-CD30 antibody binding to CD30<sup>−</sup> but not CD153<sup>−</sup> cells.

To verify the CD153/sCD30/anti-CD30 antibody interaction on the molecular level, we produced a recombinant fusion protein containing the CD153 ectodomain and GST. The protein was coupled to glutathione-coupled Sepharose beads and used in pull-down experiments. Beads were preincubated with purified sCD30.
CD153-targeting is inhibited by ADAM10-selective metalloproteinase inhibition. We directly tested the influence of the ADAM10-selective inhibitor GI254023X on the sCD30-dependent mistargeting of a CD153+ mast cell line (HMC-1). The sCD30 release of L540 cells was stimulated with Ki-1 monoclonal antibody (mAb; 3 μg/mL) in the presence or absence of GI254023X (2 μmol/L). The cell-free supernatants were used to stain HMC-1 cells. As shown by flow cytometry, ADAM10-selective shedding inhibition in a coculture experiment strongly reduced the sCD30-dependent Ki-1 binding to the CD30− mast cell line (Fig. 6).
Discussion

Three major findings emerge from the present study. First, there are at least two different mechanisms that lead to metalloproteinase-dependent CD30 shedding. One is a consequence of PKC activation. This pathway is independent of cytotoxic calcium and stimulates the CD30 cleavage through the membrane-anchored disintegrin metalloproteinase ADAM17. A second pathway is stimulated by CD30 ligation; this one is accompanied by an increase of the cytotoxic calcium, and we show here for the first time that the CD30 cleavage occurs through the disintegrin metalloproteinase ADAM10. Such antibody-induced shedding generates sCD30/antibody immune complexes. Second, the CD30 ligand (CD153), expressed on many normal cells, is not targeted by anti-CD30 antibodies but instead by sCD30/anti-CD30 antibody immune complexes, rendering antibody-stimulated shedding a significant cause of therapeutic mistargeting. Third, ADAM10 can be selectively inhibited by the metalloproteinase inhibitor GI254023X. This inhibitor blocks antibody-stimulated CD30 shedding and prevents mistargeting but has little effect on most of other metalloproteinase family members (24).

Anti-CD30 antibody binding to CD153 generally demands a bridging protein with distant antibody and ligand binding sites. Franke et al. tested the effect of different monoclonal anti-CD30 antibodies on CD30/CD153 binding (25). Antibodies of three nonoverlapping serologic clusters (clusters A–C) were included. In agreement with our data, they found no inhibition of ligand binding with the cluster B antibody Ki-1. However, in their hands, cluster A and B antibodies showed inhibition of ligand binding, which contrasts our results. A possible explanation is the fact that we used different antibodies [i.e., the original antibodies Ki-2 (A), Ki-3 (C), and Ki-4 (A)]. The latter was tested in clinical phase I studies (4, 26). As the CD30 ligand binding site has not been described thus far, and as antibodies of the same serologic cluster do not necessarily bind the same epitope, it is possible that there are some anti-CD30 antibodies that do not bind to CD153 through sCD30 bridging.

We found two different shedding mechanisms, one of which is activated by PMA, leading to ADAM17-catalyzed CD30 cleavage, and the other activated by CD30 ligation by anti-CD30 antibody, resulting in an ADAM10-catalyzed cleavage. At first glance, the finding that two enzymes account for the ectodomain release of one substrate is striking. However, to date, they are the best-analyzed releasing enzymes, and there is reported redundancy as structurally and functionally diverse proteins, such as CD44, the pro-inflammatory cytokine TNF-α and CX3CL-1, the ligands of the epidermal growth factor receptor, the interleukin-6 (IL-6) receptor, collagen XVII, or Alzheimer’s APP, were shown to be ectodomain cleaved by both enzymes (12).

Patients with CD30-expressing Hodgkin’s lymphoma or large cell anaplastic lymphoma who were treated with a therapeutic anti-CD30 antibody developed high serum levels of sCD30/anti-CD30 antibody immune complexes (4). Here, we show that immune complexes actively bind to CD153 non-target cells. In contrast to the selective overexpression of CD30 on certain lymphoma cells, CD153 is expressed on many different normal cells of the lymphatic system, such as resting B cells, activated T cells, and mast cells, monocytes, macrophages, granulocytes, and natural killer cells (2, 3). sCD30 binds to CD153 with high affinity (K_D = 4.5 nmol/L; ref. 27) and is functional on CD153-expressing normal cells as it activates neutrophils to release IL-8 for example (28). We therefore speculate that also in the in vivo situation, therapeutic anti-CD30 antibodies may bind inappropriately to CD153 on non-target normal cells, through sCD30 bridging. This finding might at least in part explain the dose-limiting cytotoxicity of therapeutic anti-CD30 antibody in clinical studies (4, 26). However, some questions remain to be solved to fully understand the clinical extent of the finding. In particular, it is unknown if CD153 normal cells are equally damaged by all types of attached anti-CD30 mAb/sCD30 immune complexes. Currently, we are investigating whether there are differences between radioimmunoconjugates that, by means of the crossfire effect, damage target cell including adjacent cell and immunotoxins that require prior internalization.

In our current study, we found that antibody-induced shedding of CD30 is the origin of therapeutic mistargeting. We also showed for the first time that this shedding process was governed by ADAM10-dependent CD30 cleavage. Shedding inhibition is desirable during the course of targeted immunotherapy against shedding-sensitive antigens. As broad-spectrum shedding inhibition in clinical studies was shown to cause substantial side effects, the knowledge of specific metalloproteinases being responsible for individual shedding events might open the possibility for pharmacologic intervention, which may benefit targeted immunotherapy. Exploiting this knowledge, we used an ADAM10-selective shedding inhibitor to block this targeting antibody-induced side effect while keeping other shedding events untouched. We regard this example as a promising approach in target immunotherapy to limit shedding-relevant side effects.

Acknowledgments

Received 7/6/2006; revised 10/16/2006; accepted 10/25/2006.

Grant support: Deutsche Krebshilfe grants 10-2144-1a and 106473 (H.P. Hansen and A. Engert), Sonderforschungsbereich 415 TPB9 (P. Saftig), and Köln Fortune (B. von Tresckow).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 USC. Section 1734 solely to indicate this fact.

We thank Frank Oberhäuser for excellent technical assistance.
References

ADAM10 Inhibition of Human CD30 Shedding Increases Specificity of Targeted Immunotherapy *In vitro*

Dennis A. Eichenauer, Vijaya Lakshmi Simhadri, Elke Pogge von Strandmann, et al.


Updated version  Access the most recent version of this article at:  http://cancerres.aacrjournals.org/content/67/1/332

Cited articles  This article cites 28 articles, 13 of which you can access for free at:  http://cancerres.aacrjournals.org/content/67/1/332.full.html#ref-list-1

Citing articles  This article has been cited by 6 HighWire-hosted articles. Access the articles at:  /content/67/1/332.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.